Form 6-K Sanofi For: Jun 08
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-31368
SANOFI
(Translation of registrant’s name into English)
46, avenue de la Grande Armée, 75017 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
1
In May 2026, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.
Exhibit Index
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press Release dated May 28, 2026: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease. | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: June 8, 2026 | SANOFI |
| By |
/s/ Alexandra Roger | |
| Name: Alexandra Roger | ||
| Title: Head of Legal Corporate & Finance |
3
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
- Unity Bank Appoints Sara M. Sooy and Alfred J. Gaburo to Board of Directors
- Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
